Zimmer Biomet Holdings, Inc. Q3 2025 Earnings Recap

Zimmer Biomet reported a 5% organic sales growth in Q3 2025, driven by strong U.S. performance, although impacted by weakness in international markets and certain product segments.

Key Takeaways

• U.S. sales accelerated to 5.6% growth, marking the highest quarterly performance since mid-2023, while technology and data sales surged by 20.3%.
• The company’s new products, such as Persona OsseoTi and robotics solutions, gained significant market traction, with U.S. knee implants performed robotically increasing 400 basis points year-over-year.
• Full-year revenue growth guidance revised to 3.5% to 4%, reflecting challenges in restorative therapies and a slowdown in the revision market, while adjusted EPS guidance remains at $8.10 to $8.30.